ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Astellas Pharma will spend up to $108 million to acquire Quethera, a British gene therapy developer founded in 2015 based on the research of a University of Cambridge professor. Quethera is using recombinant adeno-associated viral vectors to introduce therapeutic genes into retinal cells for the treatment of glaucoma. Its lead candidate has yet to enter clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X